Nanoparticle‐mediated siRNA delivery systems for cancer therapy
Abstract The small interfering RNA (siRNA)‐based therapeutics have raised great attention since the first RNA interference (RNAi)‐derived drug, patisiran, was approved by the US Food and Drug Administration, which represented a landmark in the field of gene therapy. Given the properties of interferi...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-06-01
|
| Series: | View |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/VIW.20200111 |